Siponimod: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), DMC (Denmark) and NICE (England), among others, recommended or restricted siponimod, while CIPM (Spain) and NYE METODER (Norway) did not recommend it.
Where siponimod met resistance it was usually narrowed rather than refused: 4 of 11 decisive outcomes were recommendations with restrictions, against 3 outright refusals.
Assessment has run over 5 years, from 2019 at PBAC (Australia) to 2024 at PBAC (Australia).
PBAC (Australia) changed its position: not recommended in 2019, recommended by 2024, after a resubmission.
No assessment is on file from HAS (France), which is among the eight highest-volume agencies here.
The file is active: 3 of 14 records date from 2023 or later.
5 distinct indication wordings are recorded for siponimod by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
3 of these 14 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess siponimod, in 2019; PHARMAC (New Zealand) did not open a file until 22 Dec 2023 — a wide spread of 4.4 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 8 of 14 dated records fall in 2020 alone.
Restriction is doing real work here: 4 of 11 decisive outcomes narrowed siponimod to a subgroup rather than accepting or refusing it outright, at AOTMIT (Poland), DMC (Denmark) and NICE (England) among others.
PBAC (Australia) is the only agency to have returned to siponimod, recording 3 separate entries.
siponimod has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for siponimod reads 4 recommended, 4 restricted, 3 not recommended and 1 advice, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2024 | Multiple sclerosis | Recommended | source |
| PHARMAC (New Zealand) | 22 Dec 2023 | Secondary Progressive Multiple Sclerosis (SPMS) | PTAC advice: Medium | source |
| DMC (Denmark) | 21 Jun 2023 | Sekundær progressiv multipel sklerose (SPMS) | Delvist anbefalet | source |
| NYE METODER (Norway) | 20 Jun 2021 | Behandling av sekundær progressiv multippel sklerose (SPMS) | not introduced | source |
| NICE (England) | 18 Nov 2020 | NICE TA656 | recommended (optimised) | source |
9 further decisions for siponimod, across 8 agencies, are not shown here. They link to 7 further source documents.
Related molecules
- avacopan — same ATC class L04 — Immunosuppressants
- darvadstrocel — same ATC class L04 — Immunosuppressants
- ublituximab — same ATC class L04 — Immunosuppressants
- osimertinib — also decided by PHARMAC in 2023Q4
- ofatumumab — also decided by PHARMAC in 2023Q4
- entrectinib — also decided by PHARMAC in 2023Q4
Coverage: 14 decisions for siponimod from 12 agencies, 2019 to 2024. Data to 7 Sep 2026. ATC class L04 — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.